<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00740025</url>
  </required_header>
  <id_info>
    <org_study_id>1-Sharara</org_study_id>
    <nct_id>NCT00740025</nct_id>
  </id_info>
  <brief_title>Once Daily vs Twice Daily Administration of Gonadotropins in Assisted Reproductive Technologies (ART)</brief_title>
  <acronym>QD vs BID</acronym>
  <official_title>A Prospective Randomized Study of QD vs BID Dosing in ART</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Virginia Center for Reproductive Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Virginia Center for Reproductive Medicine</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a prospective randomized study evaluating dosing frequency of gonadotropin
      administration in ART cycles.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Using once daily or bid dosing of gonadotropins in ART has been arbitrary with no studies
      showing whether splitting the medication dose improves ART parameters. This study was
      undertaken to provide an answer to this important question.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2006</start_date>
  <completion_date type="Actual">January 2010</completion_date>
  <primary_completion_date type="Actual">January 2010</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Ongoing pregnancy</measure>
    <time_frame>1 year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>peak estradiol, number of follicles, number of oocytes, implantation rate, multiple pregnancy rate</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Pregnancy</condition>
  <arm_group>
    <arm_group_label>QD</arm_group_label>
    <description>Women who received their meds as QD administration</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BID</arm_group_label>
    <description>Women who received their gonadotropins as a BID dose</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Women between 21-40 yo
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  women &lt; 40 undergoing ART

        Exclusion Criteria:

          -  women &gt; 40

          -  endometriomas

          -  severe cervical stenosis

          -  testicular sperm
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>39 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Fady I Sharara, M.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Virginia Center for Reproductive Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Virginia Center for Reproductive Medicine</name>
      <address>
        <city>Reston</city>
        <state>Virginia</state>
        <zip>20190</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 21, 2008</study_first_submitted>
  <study_first_submitted_qc>August 21, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 22, 2008</study_first_posted>
  <last_update_submitted>October 12, 2010</last_update_submitted>
  <last_update_submitted_qc>October 12, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 14, 2010</last_update_posted>
  <responsible_party>
    <name_title>Fady I. Sharara</name_title>
    <organization>Virginia Center for Reproductive Medicine</organization>
  </responsible_party>
  <keyword>QD dose</keyword>
  <keyword>BID dosing</keyword>
  <keyword>peak estradiol</keyword>
  <keyword>oocytes</keyword>
  <keyword>implantation rate</keyword>
  <keyword>pregnancy rate</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

